Lesinurad-13CD2
Added to RFQ
For Research & Analytical Purposes. Not for Personal use.
Packaging & Handling
Indicative product packaging is shown for visual reference. Actual packaging may vary based on pack size, quantity, storage condition and shipping requirements.
Documentation Available
Detailed specifications, certificates, and supporting documents are available upon request.
Detailed specifications, certificates, and supporting documents are available upon request.
Storage: Refer MSDS for complete information.
Hazard: Refer MSDS for complete information.
Lesinurad-13CD2 Product Information
Lesinurad-13CD2 is listed under Stable Isotopes and is intended for analytical research, quality control and pharmaceutical reference standard applications. It is associated with Lesinurad. The product is supplied by Clearsynth under CAT No. CS-T-103466.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
Lesinurad-13CD2
CAT No.
CS-T-103466
HSN Code
38229010
Country of Origin
Can be shipped from India, Canada and USA
Molecular Formula
C1613CH12D2BrN3O2S
Molecular Weight
407.29
Category
API Family
Storage Condition
Refer MSDS for complete information.
Hazard Compound
Refer MSDS for complete information.
Description
Regulatory Description
Lesinurad-13CD2 is supplied with detailed characterization data compliant with regulatory guideline. Lesinurad-13CD2 can be used for analytical method development, method validation (AMV), Quality Control (QC) application for Abbreviated New Drug Application (ANDA), or during commercial production of Lesinurad.
Overview
Isotope labelled Lesinurad is used to synthesize febuxostat which is a non-purine analog inhibitor of xanthine oxidase. Febuxostat is approved by the European Medicines Agency and the US Food and Drug Administration for treating gout.
Synonyms
Lesinurad-13CD2
Application Notes
Isotope labelled Lesinurad is used to synthesize febuxostat which is a non-purine analog inhibitor of xanthine oxidase. Febuxostat is approved by the European Medicines Agency and the US Food and Drug Administration for treating gout.
Product Applications & Regulatory Search Terms
Useful product, supplier and regulatory search terms for this reference standard.